Empower^™

Hereditary cancer testing, made accessible

Empower is a genetic test for those who want to know more about their risk of developing cancer, why it might be common in their family, or want to inform treatment options following a cancer diagnosis.

Empower screens for genes associated with increased risk for common hereditary cancers. Our Empower multi-cancer panels include commonly screened-for genes associated with 12+ types of cancer.

Inherited mutations can significantly increase lifetime risk for developing cancer¹

CGA-IGC webinar

GI-cancer case studies:

Utilizing oncologist-initiated testing and the new Natera Hereditary Cancer Alert Program

60 minute webinar

Featured Webinar

[GI-Cancer Case Studies] Capture More Patients & Families Who Can Benefit from Hereditary Cancer Testing: Utilizing the Natera Hereditary Cancer Alert Program and Oncologist Initiated Testing

Join Dr. Shruti Singh, Medical Oncologist / Hematologist at Northwest Cancer Centers, Natera and CGA IGC for a 60-minute webinar to discuss how providers in the Oncology clinic can initiate hereditary cancer testing through the new Natera Hereditary Cancer Alert Program to capture more patients who can benefit from genetic information.

Webinar Objectives:

Explore how to implement oncologist / clinician initiated hereditary cancer testing into workflows and the resulting impact on patient outcomes
Learn how the new Natera Hereditary Cancer Alert Program (HCAP) works to help identify more patients who meet testing guidelines in Oncology clinics

Watch Now

Learn More About Genetic Mutations & Hereditary Cancers

Hereditary Breast and Ovarian Cancer (HBOC) Syndrome

Up to 10% of all breast cancers can be attributed to hereditary causes, the most well known of which is a BRCA1 or 2 mutation. Inherited mutations can increase a woman’s risk for breast cancer to greater than 60%¹, yet up to 97% of women who carry that risk don’t know it.² Patients who know their hereditary or familial cancer risk have better outcomes than those who don’t.³

Learn More: Hereditary Breast Cancer

Amy’s Story

More Informed Treatment with Hereditary Cancer Testing

Listen to an interactive panel discussion between breast cancer patient survivors, previvors and women’s health clinicians.

“Had I known that I carried the BRCA1 mutation when I was first diagnosed, I would have had the opportunity for different treatment options. It’s an important lesson for providers – talk about family cancer history.”

AMY V. – BRCA1 mutation carrier, breast cancer survivor

Lynch Syndrome

As many as 1 in 370 people are Lynch syndrome carriers,⁴ yet 95% of them do not know.⁵ Lynch syndrome is the most common inherited cause of colon cancer and endometrial cancer. In fact, gynecologic cancer is a hallmark of Lynch syndrome. Early identification of Lynch syndrome can help manage cancer risk.^5,6,7,8

Learn More: Lynch Syndrome

How to identify and manage hereditary cancer risk

Jennifer’s Story

“I feel like the luckiest person in the world to have this information. I can be a previvor. I can take control of my health now and make sure that I don’t ever have to deal with uterine or colon cancer like every woman in my maternal line has so far.”

JENNIFER PLENT – Lynch syndrome mutation carrier, cancer previvor

How it works

Provider orders an Empower Hereditary Cancer Test.

Patient provides a blood or saliva sample.

Patients review results with their provider in about 2 weeks.

Actionable reports guide next steps, including:

Detect cancer at its earliest, most treatable stage
Identify risk-reducing medications and surgeries
Inform surgical and therapeutic decisions following a cancer diagnosis
Notify family members to help them proactively manage hereditary cancer risk

Making the difference for families with hereditary cancer

“Our mom isn’t here to walk us through this journey.” Hannah and Katie made proactive health plans together after learning they carry a BRCA1 mutation.

NEVA, Natera Educational Virtual Assistant

Streamlined family cancer history intake
Interactive results delivery and genetic education, available 24/7

Learn more

Is Empower right for you? Contact us.

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹NCCN Guidelines Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer v.3.2023

²Knerr S, et al. Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015. J Natl Cancer Inst. 2019 Aug 1;111(8):795-802. doi: 10.1093/jnci/djz008. PMID: 30753636; PMCID: PMC6695306.

³Domchek SM et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 1;304(9):967-75. doi:10.1001/jama.2010.1237. PMID: 20810374; PMCID: PMC2948529.

⁴Hampel H, de la Chapelle A. “How do we approach the goal of identifying everybody with Lynch syndrome?” Familial Cancer, Jun. 2013, https://pubmed.ncbi.nlm.nih.gov/23568035/.

⁵Lowry, Blue Ribbon Panel Report. 2016. https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel#ui-id-3

⁶Cancer.net editorial board. “Lynch Syndrome.” Cancer.Net, 11 Aug. 2021, https://www.cancer.net/cancer-types/lynch-syndrome.

⁷Surveillance, Epidemiology and End Results (SEER) Program (https://seer.cancer.gov/)

⁸Rubenstein JH et al. American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Lynch Syndrome. Gastroenterology. 2015 Sep;149(3):777-82; quiz e16-7.f

Empower™